Company: MYGN
Filing Date: 2025-04-09
Form Type: DEF 14A
Source: 0000899923-25-000028
Chunk: 93

Company: MYRIAD GENETICS INC
Filing Date: 2025-04-09
Form: DEF 14A
Chunk 93
---
 stock units and/or other equity awards granted will be determined by dividing $350,000 by the closing price of our common stock on the Nasdaq Global Select Market on the date of the applicable annual meeting of stockholders or the date that such new non-employee director is appointed to the Board, as applicable. In the case of a prorated equity award, the number of shares of restricted stock, restricted stock units and/or other equity awards granted will be determined by dividing the value of the prorated award by the closing price of our common stock on the Nasdaq Global Select Market on the date of the applicable annual meeting of stockholders. Notwithstanding the foregoing, in no event will a non-employee director receive equity awards under the 2017 Plan with an aggregate grant date fair value in excess of $500,000 during any calendar year.

Restricted stock, restricted stock units, and other equity awards granted to our non-employee directors may vest, in the discretion of the Board and/or the CHCC, (1) in the case of awards granted on the date of our annual meeting of stockholders, upon the earlier of (i) one year of service on the Board following the date of grant or (ii) the date of the next annual meeting of stockholders following such grant and (2) in the case of awards granted on the date that a new non-employee director is appointed to the Board, on the date that is one year following the date of such grant.

62

#### Equity Compensation Plan Information
The following table provides certain aggregate information with respect to all of the Company’s equity compensation plans in effect as of December 31, 2024:

| Plan Category                                                  |     |                                                                                         (a) 
 Number of securities to be issued upon exercise of outstanding options, warrants and rights |     |                                                                         (b) 
 Weighted-average exercise price of outstanding options, warrants and rights |     |                                                                                                                                            -c) 
 Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) (3 |
| Equity compensation plans approved by security holders (1)     |     |                                                                                   5,233,393 |     |                                                                           — |     |                                                                                                                                      3,123,622 |
| Equity compensation plans not approved by security holders (2) |     |                                                                                     681,128 |     |                                                                      $13.38 |     |                                                                                                                                              — |
| Total                                                          |     |                                                                                   5,914,521 |